These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21326940)

  • 1. Bacteria as tumor therapeutics?
    Oelschlaeger TA
    Bioeng Bugs; 2010; 1(2):146-7. PubMed ID: 21326940
    [No Abstract]   [Full Text] [Related]  

  • 2. Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice.
    Stritzker J; Hill PJ; Gentschev I; Szalay AA
    Bioeng Bugs; 2010; 1(2):139-45. PubMed ID: 21326939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotics for cancer alternative prevention and treatment.
    Legesse Bedada T; Feto TK; Awoke KS; Garedew AD; Yifat FT; Birri DJ
    Biomed Pharmacother; 2020 Sep; 129():110409. PubMed ID: 32563987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteria-mediated disease therapy.
    Yu H
    Appl Microbiol Biotechnol; 2011 Dec; 92(6):1107-13. PubMed ID: 22033568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental biology of gut-probiotic interaction.
    Patel RM; Lin PW
    Gut Microbes; 2010; 1(3):186-95. PubMed ID: 21327024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial therapies: completing the cancer treatment toolbox.
    St Jean AT; Zhang M; Forbes NS
    Curr Opin Biotechnol; 2008 Oct; 19(5):511-7. PubMed ID: 18760353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host.
    Gronbach K; Eberle U; Müller M; Olschläger TA; Dobrindt U; Leithäuser F; Niess JH; Döring G; Reimann J; Autenrieth IB; Frick JS
    Infect Immun; 2010 Jul; 78(7):3036-46. PubMed ID: 20421387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional foods: at the frontier between food and pharma.
    Mollet B; Rowland I
    Curr Opin Biotechnol; 2002 Oct; 13(5):483-5. PubMed ID: 12459341
    [No Abstract]   [Full Text] [Related]  

  • 9. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.
    Dailey KM; Allgood JE; Johnson PR; Ostlie MA; Schaner KC; Brooks BD; Brooks AE
    Future Microbiol; 2021 Mar; 16(5):341-368. PubMed ID: 33754804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of probiotic strains on interleukin 8 production by HT29/19A cells.
    Lammers KM; Helwig U; Swennen E; Rizzello F; Venturi A; Caramelli E; Kamm MA; Brigidi P; Gionchetti P; Campieri M
    Am J Gastroenterol; 2002 May; 97(5):1182-6. PubMed ID: 12014725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotic Properties of Escherichia coli Nissle in Human Intestinal Organoids.
    Pradhan S; Weiss AA
    mBio; 2020 Jul; 11(4):. PubMed ID: 32636253
    [No Abstract]   [Full Text] [Related]  

  • 12. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1.
    Ukena SN; Westendorf AM; Hansen W; Rohde M; Geffers R; Coldewey S; Suerbaum S; Buer J; Gunzer F
    BMC Med Genet; 2005 Dec; 6():43. PubMed ID: 16351713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics from research to market: the possibilities, risks and challenges.
    Foligné B; Daniel C; Pot B
    Curr Opin Microbiol; 2013 Jun; 16(3):284-92. PubMed ID: 23866974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
    Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities.
    Kalyoncu E; Olmez TT; Ozkan AD; Sarioglu OF
    Curr Pharm Des; 2016; 22(11):1521-8. PubMed ID: 26654438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic E. coli Nissle 1917 biofilms on silicone substrates for bacterial interference against pathogen colonization.
    Chen Q; Zhu Z; Wang J; Lopez AI; Li S; Kumar A; Yu F; Chen H; Cai C; Zhang L
    Acta Biomater; 2017 Mar; 50():353-360. PubMed ID: 28069496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospects of the development of probiotic preparations on the basis of the "quorum sensing" in bacteria].
    Vakhitov TIa; Petrov LN; Bondarenko VM; Vorob'ev AA
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (3):105-13. PubMed ID: 16830603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens.
    Altenhoefer A; Oswald S; Sonnenborn U; Enders C; Schulze J; Hacker J; Oelschlaeger TA
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):223-9. PubMed ID: 15039098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aspects of probiotics--a novel approach in the management of food allergy.
    Kirjavainen PV; Apostolou E; Salminen SJ; Isolauri E
    Allergy; 1999 Sep; 54(9):909-15. PubMed ID: 10505453
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolerogenic probiotics: potential immunoregulators in Systemic Lupus Erythematosus.
    Esmaeili SA; Mahmoudi M; Momtazi AA; Sahebkar A; Doulabi H; Rastin M
    J Cell Physiol; 2017 Aug; 232(8):1994-2007. PubMed ID: 27996081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.